rct
    2009

    Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study

    Ye P, Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, Zhao YC

    Published in Journal of Clinical Pharmacology

    Key Findings

    In elderly hypertensive post-infarction patients, Xuezhikang reduced coronary events and cardiovascular mortality compared with placebo.

    Conclusions

    Benefits extended to elderly hypertensive subgroups.

    Limitations

    Subgroup analysis of a single large trial.

    Supplements Studied

    In elderly hypertensive post-infarction patients Xuezhikang reduced coronary events and cardiovascular mortality.

    Outcomes Measured

    Cardiovascular Risk Reduction

    Xuezhikang reduced coronary events and cardiovascular mortality in elderly hypertensive patients.

    Related Health Concerns

    Cardiovascular Disease

    Study Details

    Year:2009
    Sample Size:1,530
    Duration:234 weeks
    Quality Score:6/10

    Access Study

    View on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.